EAST HANOVER, N.J.,
April 23, 2014 /PRNewswire/
-- Novartis Pharmaceuticals Corporation (NPC) has been named
the leading company on the 14th annual DiversityInc Top
50 Companies for Diversity listing. DiversityInc announced the
results of its 2014 Top 50 Companies for Diversity on April 22 at an awards ceremony in New York, NY.
"We are extremely honored to be recognized by DiversityInc,"
said Andre Wyss, President, Novartis
Pharmaceuticals Corporation and President, Novartis Corporation. "We have worked hard to
make diversity and inclusion a very natural part of the way we do
business because we fundamentally believe it drives innovation,
moves our business and our people forward, and most importantly –
directly impacts our ability to develop lifesaving products and
solutions. We are proud of the progress we have made and this
achievement inspires us to continue this important effort."
The rankings are determined by an objective methodology that
calculates factors such as Talent Pipeline, Equitable Talent
Development (including commitments to mentorship and philanthropy),
CEO/Leadership Commitment, and Supplier Diversity. The empirical
data for the rankings is provided by a 300-question survey filled
out by personnel at the participating companies. Survey
participation is free to any company with at least 1,000 US
workers.
DiversityInc also announced a number of Specialty Lists. NPC
ranked second on the DiversityInc list of Top Ten Companies for
Recruitment.
"We thank our associates for their energy, commitment and
collaboration that have brought diversity and inclusion to life in
our organization, to support our patients, customers and the
communities we serve. Moving forward, we will continue to leverage
diversity and inclusion to stimulate innovation and business growth
and reinforce our position as an employer of choice by exploring
enhanced flexibility and new ways of working," said Rhonda Crichlow, vice president and head, US
diversity and inclusion at Novartis Pharmaceuticals
Corporation.
"The support and personal involvement of company leadership has
propelled NPC to the top of the list. With their guidance, the
company has made dramatic progress – today, women make up more
than 50 percent of the NPC executive committee, including
scientific positions," said DiversityInc founder and CEO,
Luke Visconti.
For the entire list, go to
http://www.diversityinc.com/top50.
Disclaimer
This press release contains expressed or
implied forward-looking statements, including statements that can
be identified by terminology such as "commitment," "moving
forward," "will," or similar expressions. Such forward-looking
statements reflect the current views of the Group regarding future
events, and involve known and unknown risks, uncertainties and
other factors that may cause actual results to be materially
different from any future results expressed or implied by such
statements. These expectations could be affected by, among other
things, risks and factors referred to in the Risk Factors section
of Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in
this press release as of this date and does not undertake any
obligation to update it in the future.
About Novartis
Novartis Pharmaceuticals Corporation
researches, develops, manufactures and markets innovative medicines
aimed at improving patients' lives. We offer a broad range of
medicines for cancer, cardiovascular disease, endocrine disease,
inflammatory disease, infectious disease, neurological disease,
organ transplantation, psychiatric disease, respiratory disease and
skin conditions. The company's mission is to improve people's
lives by pioneering novel healthcare solutions.
Located in East Hanover, New
Jersey, Novartis Pharmaceuticals Corporation is an affiliate
of Novartis AG, which provides innovative healthcare solutions that
address the evolving needs of patients and societies. Headquartered
in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals,
preventive vaccines and diagnostic tools, over-the-counter and
animal health products. Novartis is the only global company with
leading positions in these areas. In 2013, the Group achieved net
sales of USD 57.9 billion, while
R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6
billion excluding impairment and amortization charges).
Novartis Group companies employ approximately 136,000
full-time-equivalent associates and operate in more than 140
countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis.
Novartis Media Relations
Julie
Masow
Novartis Media
Relations
+1 212 830 2465
(direct)
+1 862 579 8456
(mobile)
julie.masow@novartis.com
e-mail:
us.mediarelations@novartis.com
|
Anna
Frable
Novartis
Pharmaceuticals Corporation
+1 862-778-5388
(direct)
+1 732-673-5262
(mobile)
anna.frable@novartis.com
|
SOURCE Novartis Pharmaceuticals Corporation